PMID- 23414642
OWN - NLM
STAT- MEDLINE
DCOM- 20131101
LR  - 20151119
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 80
IP  - 2
DP  - 2013 May
TI  - Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer 
      patients: a retrospective study.
PG  - 197-202
LID - S0169-5002(13)00025-1 [pii]
LID - 10.1016/j.lungcan.2013.01.015 [doi]
AB  - BACKGROUND: Combination of bevacizumab and weekly paclitaxel showed synergitic 
      effects, anti-tumor efficacy and a good toxicity profile for patients with breast 
      cancer but has never been evaluated in non small cell lung cancer (NSCLC). We 
      retrospectively reviewed safety and efficacy of this regimen in metastatic 
      non-squamous NSCLC as fourth-line therapy or beyond. METHODS: Patients were 
      identified from a prospective database. Treatment consisted in paclitaxel 80 
      mg/m(2) on days 1, 8 and 15 and bevacizumab 15 mg/kg on day 1, every 3 weeks 
      until progression or unacceptable toxicity. RESULTS: Twenty patients were 
      included in this study. Objective response rate at first evaluation was 40% 
      (8/20), confirmed response rate was 15% (3/20) and disease control rate was 75% 
      (15/20). The median progression-free survival and overall survival were 6.4 
      months (CI95% 4.1-9) and 9.6 months (CI95% 7-19.7). Grade 3-4 adverse events 
      included neutropenia (4/20), onycholysis (2/20) and infection (2/20). One patient 
      died from a bowel perforation and another one died from unknown cause. Prolonged 
      responses were observed in a patient who had received bevacizumab as part of 
      first-line chemotherapy and in another one who harbored an ALK rearrangement. 
      CONCLUSIONS: In our experience, combination of bevacizumab and weekly paclitaxel 
      exhibited acceptable toxicity and had encouraging anti-tumor efficacy as 
      fourth-line treatment or beyond for non-squamous NSCLC patients, supporting 
      further evaluation in larger prospective studies.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Habib, Stefanie
AU  - Habib S
AD  - Pulmonary and Thoracic Oncology Department, CHRU of Lille, France.
FAU - Delourme, Julie
AU  - Delourme J
FAU - Dhalluin, Xavier
AU  - Dhalluin X
FAU - Petyt, Gregory
AU  - Petyt G
FAU - Tacelli, Nunzia
AU  - Tacelli N
FAU - Scherpereel, Arnaud
AU  - Scherpereel A
FAU - Lafitte, Jean-Jacques
AU  - Lafitte JJ
FAU - Cortot, Alexis B
AU  - Cortot AB
LA  - eng
PT  - Journal Article
DEP - 20130214
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects
MH  - Bevacizumab
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/chemically induced/pathology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis/*drug therapy
MH  - Neoplasm Staging
MH  - Paclitaxel/*administration & dosage/adverse effects
MH  - Prospective Studies
EDAT- 2013/02/19 06:00
MHDA- 2013/11/02 06:00
CRDT- 2013/02/19 06:00
PHST- 2012/11/27 00:00 [received]
PHST- 2013/01/18 00:00 [revised]
PHST- 2013/01/19 00:00 [accepted]
PHST- 2013/02/19 06:00 [entrez]
PHST- 2013/02/19 06:00 [pubmed]
PHST- 2013/11/02 06:00 [medline]
AID - S0169-5002(13)00025-1 [pii]
AID - 10.1016/j.lungcan.2013.01.015 [doi]
PST - ppublish
SO  - Lung Cancer. 2013 May;80(2):197-202. doi: 10.1016/j.lungcan.2013.01.015. Epub 
      2013 Feb 14.